| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jenny Bischoff, Charlotte Fries, Alexander Heer, Friederike Hoffmann, Carsten Meyer, Jennifer Landsberg, Wiebke K Fensk. It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia. Journal of the Endocrine Society. vol 6. issue 5. 2022-03-31. PMID:35356006. |
we report here 3 cases of different endocrine iraes, first manifesting with new-onset hyponatremia under ici therapy for malignant melanoma: one with primary adrenal insufficiency, one with hypophysitis, and one with autoimmune type 1 diabetes. |
2022-03-31 |
2023-08-13 |
Not clear |
| Anupam Kotwal, Samuel G Rouleau, Surendra Dasari, Lisa Kottschade, Mabel Ryder, Yogish C Kudva, Svetomir Markovic, Dana Erickso. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2021-12-31. PMID:34969937. |
secondary adrenal insufficiency occurred in all hypophysitis cases. |
2021-12-31 |
2023-08-13 |
Not clear |
| S Coniac, M Stoia. UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY. Acta endocrinologica (Bucharest, Romania : 2005). vol 17. issue 2. 2021-12-20. PMID:34925584. |
endocrinopathy such as thyroid dysfunctions, hypophysitis, primary adrenal insufficiency, type 1 diabetes mellitus, central diabetes insipidus, or hypoparathyroidism were reported and called immune-related adverse effects (iraes). |
2021-12-20 |
2023-08-13 |
Not clear |
| Khyatisha Seejore, Marilena Giannoudi, Djoah Osborn, Julie M Lynch, Ahmed Al-Qaissi, Elaine Dunwoodie, Jane Hook, Maria Marples, Robert D Murra. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis. European journal of endocrinology. vol 186. issue 1. 2021-12-03. PMID:34735371. |
characterisation of the onset and severity of adrenal and thyroid dysfunction associated with ctla4-related hypophysitis. |
2021-12-03 |
2023-08-13 |
Not clear |
| S A Paschou, K Stefanaki, T Psaltopoulou, M Liontos, K Koutsoukos, F Zagouri, I Lambrinoudaki, M-A Dimopoulo. How we treat endocrine complications of immune checkpoint inhibitors. ESMO open. vol 6. issue 1. 2021-10-29. PMID:33399077. |
endocrine complications are among the most common, including hypophysitis, thyroid dysfunction, diabetes mellitus and primary adrenal insufficiency, while autoimmune polyendocrine syndrome type 2 (aps-2) may also present. |
2021-10-29 |
2023-08-13 |
Not clear |
| Sumit S Patel, Sasmit Roy, Mytri Pokal, Vijay Gayam, Sreedhar Adapa, Eesha S Pate. Hyponatremia and Fever in a Patient on Ipilimumab and Nivolumab (Immune Checkpoint Inhibitors): A Case Report. Journal of investigative medicine high impact case reports. vol 9. 2021-10-15. PMID:34538118. |
there are different mechanisms leading to hyponatremia in patients on icis, which could be (1) hypovolemic hyponatremia due to hemodynamic disturbance secondary to volume depletion (eg, from irae like colitis and enteritis) or hypervolemia due to congestive heart failure, cirrhosis, or nephrosis; (2) syndrome of inappropriate antidiuretic hormone (siadh) secretion (especially from underlying lung cancer or neurological irae like encephalitis and meningitis) with elevated urine sodium and urine osmolarity; and (3) irae-related endocrinopathies such as hypophysitis, adrenal insufficiency, and hypothyroidism leading to euvolemic hyponatremia. |
2021-10-15 |
2023-08-13 |
Not clear |
| Smile Kajal, Pooja Gupta, Anam Ahmed, Anurag Gupt. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer. Drug discoveries & therapeutics. vol 15. issue 4. 2021-09-24. PMID:34456195. |
we report development of hypophysitis in an 84-year-old female patient who developed a range of symptoms (fatigue, headache, nausea) as well as laboratory confirmation of both central hypothyroidism and central adrenal deficiency which is unusual in cases of nivolumab induced hypophysitis. |
2021-09-24 |
2023-08-13 |
Not clear |
| Jordan J Wright, Alvin C Powers, Douglas B Johnso. Endocrine toxicities of immune checkpoint inhibitors. Nature reviews. Endocrinology. vol 17. issue 7. 2021-09-23. PMID:33875857. |
importantly, iraes can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). |
2021-09-23 |
2023-08-13 |
Not clear |
| Yaxian Yang, Jingfang Liu, Kaili Yang, Yanqi Ma, Songbo Fu, Xulei Tang, Yan Wang, Liyuan Zho. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review. Journal of clinical pharmacology. vol 61. issue 3. 2021-07-26. PMID:33345342. |
compared with the other tumor therapies (used as a control group), patients treated with programmed death-1 inhibitors appeared to be at higher risks of hypothyroidism, hyperthyroidism, thyroiditis, hypophysitis or hypopituitarism, and type 1 diabetes mellitus, while there was no difference in the risk of primary adrenal insufficiency. |
2021-07-26 |
2023-08-13 |
Not clear |
| Yaxian Yang, Jingfang Liu, Kaili Yang, Yanqi Ma, Songbo Fu, Xulei Tang, Yan Wang, Liyuan Zho. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review. Journal of clinical pharmacology. vol 61. issue 3. 2021-07-26. PMID:33345342. |
it was also found that patients treated with cytotoxic t-lymphocyte-associated protein-4 inhibitors were at higher risk of hypophysitis or hypopituitarism, primary adrenal insufficiency, and hypothyroidism. |
2021-07-26 |
2023-08-13 |
Not clear |
| Yudai Hinata, Nobumasa Ohara, Yuhki Sakurai, Ryo Koda, Yuichiro Yoneoka, Toshinori Takada, Noboru Hara, Tsutomu Nishiyam. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review. The American journal of case reports. vol 22. 2021-07-16. PMID:34262010. |
one of the common endocrine iraes is hypophysitis, which often causes hypopituitarism with secondary adrenal insufficiency (ai). |
2021-07-16 |
2023-08-13 |
Not clear |
| Anna Angelousi, Krystallenia Alexandraki, Marina Tsoli, Gregory Kaltsas, Eva Kass. Hypophysitis (Including IgG4 and Immunotherapy). Neuroendocrinology. vol 110. issue 9-10. 2021-07-08. PMID:32126548. |
hypophysitis can occur silently and be easily missed, potentially leading to substantial morbidity or mortality due to adrenal insufficiency, requiring a high index of clinical suspicion and timely initiation of appropriate treatment. |
2021-07-08 |
2023-08-13 |
Not clear |
| Neena Baby, Prasanth Varghese, Sabu George Kunnathuparambil, Aneesh Mangalasseril Kuriakos. Hypophysitis: A Rare Cause of Impaired Consciousness in a Middle-Aged Woman. Neurology India. vol 68. issue 5. 2021-06-21. PMID:33109880. |
hypophysitis involving the anterior pituitary often presents with adrenal insufficiency. |
2021-06-21 |
2023-08-13 |
Not clear |
| Jaydira Del Rivero, Lisa M Cordes, Joanna Klubo-Gwiezdzinska, Ravi A Madan, Lynnette K Nieman, James L Gulle. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. The oncologist. vol 25. issue 4. 2021-06-18. PMID:32297436. |
multiple endocrine iraes, including primary hyperthyroidism and hypothyroidism, thyroiditis, primary adrenal insufficiency, type 1 diabetes mellitus, and hypophysitis, have been reported with the use of various immune checkpoint inhibitors. |
2021-06-18 |
2023-08-13 |
Not clear |
| Stuti Fernandes, Elena V Varlamov, Shirley McCartney, Maria Fleseri. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors. Endocrinology and metabolism clinics of North America. vol 49. issue 3. 2021-06-18. PMID:32741478. |
treatment with high-dose glucocorticoids and temporary cessation of immunotherapy is indicated for severe hypophysitis with intractable headaches and vision changes, and for adrenal crisis. |
2021-06-18 |
2023-08-13 |
Not clear |
| Viny Kantroo, Saptarshi Bhattacharya, Atul Dhingra, Sanjay Kalr. Pulmocrinology: Interplay of pulmonary and endocrine diseases. JPMA. The Journal of the Pakistan Medical Association. vol 71. issue 3. 2021-06-02. PMID:34057973. |
varied manifestations such as primary adrenal insufficiency, hypophysitis and hypercalcaemia can result from chronic granulomatous conditions like tuberculosis and sarcoidosis. |
2021-06-02 |
2023-08-13 |
Not clear |
| Ansgar Heck, Anna K Winge-Mai. Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors. BMJ case reports. vol 14. issue 5. 2021-05-31. PMID:34045201. |
most cases with ici-induced hypophysitis develop central adrenal insufficiency. |
2021-05-31 |
2023-08-13 |
Not clear |
| Rosie Hattersley, Melanie Nana, Andrew J Lansdow. Endocrine complications of immunotherapies: a review. Clinical medicine (London, England). vol 21. issue 2. 2021-05-20. PMID:33762389. |
thyroid disease and hypophysitis are the most commonly encountered, with diabetes mellitus and primary adrenal insufficiency also reported, as well as more rare endocrinopathies. |
2021-05-20 |
2023-08-13 |
Not clear |
| Natalia G Deligiannis, Soledad Sosa, Karina Danilowicz, Leonardo F L Rizz. Endocrine dysfunction induced by immune checkpoint inhibitors. Medicina. vol 81. issue 2. 2021-04-29. PMID:33906146. |
immune-related endocrine toxicities include thyroid dysfunction, hypophysitis and, less frequently, type 1 diabetes, primary adrenal insufficiency and hypoparathyroidism. |
2021-04-29 |
2023-08-13 |
Not clear |
| Maria Stelmachowska-Banaś, Izabella Czajka-Oranie. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine connections. vol 9. issue 10. 2021-01-10. PMID:33064663. |
we present updated information on the incidence and clinical development of ici-induced endocrinopathies, including the most frequent thyroiditis and hypophysitis, the rarely observed insulin-dependent diabetes mellitus and primary adrenal insufficiency, and the recently described cases of hypoparathyroidism and lipodystrophy. |
2021-01-10 |
2023-08-13 |
Not clear |